• Technology enhances vaccine stability, which translates into greater potency and improved safety – and reduced costs
    • Lower cost of goods & lower cold-chain requirements
  • Sophisticated, nano-scale bioprocess-technology leverages natural enzymatic reaction:
    • Locks vaccines in 3D shapes that maximize efficacy and prolong shelf life, reducing cold-chain requirements
    • Economic engineering minimizes risks
  • Compatible with standard biologics manufacturing
    • Substantial synergies between programs
  • Applying technology generates NCEs and supports novel composition of matter patents to enhance broad IP protection